#1 Clinical Trials Search in Europe

Blinatumomab

Blinatumomab is an innovative drug being studied in clinical trials for the treatment of acute lymphoblastic leukemia (ALL), a type of blood cancer. This article explores the use of blinatumomab in various clinical trials, its potential benefits, and its impact on patients with different forms of ALL, including those with minimal residual disease (MRD) and relapsed/refractory cases.

Table of Contents

What is Blinatumomab?

Blinatumomab, also known by its brand name Blincyto®, is a specialized medication used in the treatment of certain types of blood cancers[1]. It belongs to a class of drugs called bispecific T-cell engagers (BiTE®)[2]. This means that blinatumomab is designed to connect two different types of cells in your body: T-cells (a type of immune cell) and B-cells (where the cancer originates in the conditions it treats).

What Conditions Does Blinatumomab Treat?

Blinatumomab is primarily used to treat several types of blood cancers, including:

  • B-cell precursor Acute Lymphoblastic Leukemia (B-ALL): This is a type of cancer that affects the blood and bone marrow, specifically targeting B-cells (a type of white blood cell)[1].
  • Relapsed or Refractory (R/R) B-ALL: This refers to B-ALL that has either come back after treatment (relapsed) or has not responded well to initial treatments (refractory)[2].
  • Mixed Phenotype Acute Leukemia (MPAL): This is a rare type of leukemia that shows features of both acute lymphoblastic leukemia and acute myeloid leukemia[2].
  • B-cell Non-Hodgkin Lymphoma: This is a type of cancer that starts in B-cells and affects the lymphatic system[3].

How Does Blinatumomab Work?

Blinatumomab works in a unique way compared to traditional cancer treatments. It acts as a bridge between two types of cells in your body:

  1. T-cells: These are part of your immune system and can kill cancer cells when activated.
  2. B-cells: In the cancers that blinatumomab treats, these are the cells that have become cancerous.

Blinatumomab attaches to a specific protein called CD19 on the surface of cancerous B-cells and to CD3 on T-cells. By bringing these cells together, it helps your body’s T-cells recognize and destroy the cancerous B-cells[2].

How is Blinatumomab Administered?

Blinatumomab is typically given as a continuous intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The treatment is usually administered in cycles, with each cycle lasting about 4-6 weeks[3]. The exact dosing and schedule can vary depending on your specific condition and treatment plan. For example:

  • In some cases, the dose may start lower and then increase over the first few days of treatment[1].
  • For children, the dose is often calculated based on body surface area[4].
  • Some studies are exploring the use of subcutaneous (under the skin) injections of blinatumomab instead of IV infusions[5].

Efficacy of Blinatumomab

Clinical trials have shown promising results for blinatumomab in treating various forms of leukemia and lymphoma. Some key findings include:

  • Improved complete remission rates in patients with relapsed or refractory B-ALL[2].
  • Potential effectiveness in clearing minimal residual disease (MRD), which refers to small numbers of cancer cells that remain after treatment[6].
  • Possible benefits in preparing patients for stem cell transplantation[7].

However, it’s important to note that the effectiveness can vary from person to person, and more research is ongoing to fully understand the long-term benefits of blinatumomab.

Potential Side Effects

Like all medications, blinatumomab can cause side effects. Some of the potential side effects that have been observed in clinical trials include:

  • Cytokine Release Syndrome (CRS): This is a condition where your immune system becomes highly activated, potentially causing fever, chills, and other flu-like symptoms[8].
  • Neurological effects: Some patients may experience confusion, tremors, or difficulty speaking[3].
  • Infections: Because blinatumomab affects your immune system, it may increase your risk of infections[8].
  • Hematological effects: Changes in blood cell counts may occur[8].

Your healthcare team will monitor you closely for these and other potential side effects during treatment.

Ongoing Research and Clinical Trials

Researchers continue to study blinatumomab to better understand its effects and explore new ways to use it. Some areas of ongoing research include:

  • Use in newly diagnosed patients with B-ALL[1].
  • Combination with other treatments, such as chemotherapy or stem cell transplantation[7].
  • Different methods of administration, such as subcutaneous injections[5].
  • Use in specific patient populations, such as infants with leukemia[4].

These ongoing studies aim to improve treatment outcomes and potentially expand the use of blinatumomab to help more patients with blood cancers.

Aspect Details
Drug Name Blinatumomab (also known as Blincyto, AMG 103)
Primary Indications Acute Lymphoblastic Leukemia (ALL), B-cell precursor ALL, Relapsed/Refractory ALL, Minimal Residual Disease (MRD) positive ALL
Administration Method Continuous intravenous infusion, typically over 28-day cycles
Key Outcomes Measured Complete remission rates, MRD response, Overall survival, Progression-free survival, Duration of response
Patient Populations Adults and children with various forms of ALL, including newly diagnosed, relapsed/refractory, and MRD-positive cases
Safety Monitoring Adverse events, including neurological events, cytokine release syndrome, and infections
Additional Assessments Quality of life measures, pharmacokinetics, potential for stem cell transplantation

FAQ

  • What is blinatumomab? Blinatumomab is a bispecific T-cell engager antibody that links B cells and T cells, activating T cells to target and destroy cancer cells that express CD19, a protein found on the surface of B cells.
  • What types of leukemia is blinatumomab being studied for? Blinatumomab is primarily being studied for various forms of acute lymphoblastic leukemia (ALL), including B-cell precursor ALL, relapsed/refractory ALL, and ALL with minimal residual disease (MRD).
  • How is blinatumomab administered in clinical trials? In most trials, blinatumomab is administered as a continuous intravenous infusion over several weeks, with specific dosing schedules varying between studies.
  • What are some potential benefits of blinatumomab treatment? Clinical trials have shown that blinatumomab may help achieve complete remission, reduce minimal residual disease, improve survival rates, and serve as a bridge to stem cell transplantation in some patients with ALL.
  • Are there any side effects associated with blinatumomab? Like all medications, blinatumomab can cause side effects. Common side effects reported in trials include fever, headache, and neurological events. The severity and frequency of side effects are closely monitored in clinical trials.

Ongoing Clinical Trials on Blinatumomab

  • Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy The Netherlands +1

  • A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France Italy The Netherlands

  • A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Romania +1

  • Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +5

  • Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Adding Blinatumomab to Treatment for Adults with Precursor B-Acute Lymphoblastic Leukemia

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium The Netherlands

  • Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Germany Italy Slovakia

  • Study on Acute Lymphoblastic Leukemia Treatment in Children and Adolescents Using Bortezomib, Blinatumomab, and Methotrexate Combination

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Poland

Glossary

  • Acute Lymphoblastic Leukemia (ALL): A type of blood cancer that affects the lymphoid cells in the bone marrow, causing rapid growth of abnormal white blood cells.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body after treatment, which can be detected by highly sensitive tests but not by standard methods.
  • Relapsed/Refractory (R/R): Refers to cancer that has returned after treatment (relapsed) or has not responded to initial treatment (refractory).
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy stem cells, which can develop into new, healthy blood cells.
  • Complete Remission (CR): A state where there is no evidence of disease and blood counts have returned to normal levels after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the disease getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to perform daily activities, often assessed in clinical trials to understand the impact of treatment on patients' lives.

References

  1. https://clinicaltrials.gov/study/NCT06649006
  2. https://clinicaltrials.gov/study/NCT04827745
  3. https://clinicaltrials.gov/study/NCT02910063
  4. https://clinicaltrials.eu/trial/study-on-methotrexate-and-dexamethasone-for-infants-under-one-year-with-acute-lymphoblastic-leukemia/
  5. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-subcutaneous-blinatumomab-in-adults-and-adolescents-with-relapsed-refractory-or-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblast/
  6. https://clinicaltrials.gov/study/NCT05827549
  7. https://clinicaltrials.gov/study/NCT06125106
  8. https://clinicaltrials.gov/study/NCT06339775